ESC: Alnylam’s Aim For First-Line Amvuttra Use Looks Dicey
The full pivotal data in ATTR cardiomyopathy suggest the transthyretin silencer could find a niche as an add-on to Pfizer’s established drug Vyndamax.
The full pivotal data in ATTR cardiomyopathy suggest the transthyretin silencer could find a niche as an add-on to Pfizer’s established drug Vyndamax.